Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 January 2021 | Story André Damons | Photo Supplied
Vincent Clarke
Dr Ralph Clark

The Afromontane Research Unit (ARU), the flagship research group of the University of the Free State (UFS) Qwaqwa Campus, has recently been granted R8,4 million to establish a Risk and Vulnerability Science Centre programme.

The Risk and Vulnerability Science Centre (RVSC) programme was established by the Department of Science and Innovation (DSI) as part of the Global Change Research Plan for South Africa and is funded by the DSI through the National Research Foundation (NRF). The RVSC will focus on the need to generate and disseminate knowledge about risk and vulnerability on global change challenges faced by local policy makers/ governance structures and communities in South Africa.

Invited to participate  

Dr Ralph Clark, Director of the ARU, says the UFS, together with the University of Zululand and the Sol Plaatje University, has been invited to participate in Phase 2 of the RVSC programme. Dr Clark was approached by the DSI (on referral from the South African Environmental Observation Network – SAEON) in February 2020 regarding the potential for establishing a RVSC at the UFS Qwaqwa campus.

Subsequent interactions were held between the UFS and DSI, and in March 2020, the UFS formally accepted the DSI invitation. It has since been agreed that the RVSC: UFS will be hosted as a RVSC under the ARU umbrella, with dedicated personnel embedded at the UFS in this regard (internal processes and reporting) but reporting directly to the NRF regarding the RVSC.

Interest and support welcomed

Dr Clark welcomed this interest and support from the DSI-NRF, saying that the funds will further assist the UFS in growing its excellent and growing research portfolio and building more research capacity on this traditionally undergraduate-focused campus. “The RVSC will contribute to much-needed solutions in an area marked by major sustainability challenges and will assist in moving Phuthaditjhaba away from its negative apartheid history towards becoming a sustainable African mountain city,” says Dr Clark.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept